Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
+46.12 (0.82%)
Jul 29 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 5,590.00 - 5,754.67
52 week 34.48 - 5,754.67
Open 5,630.00
Vol / Avg. 1.52M/1.22M
Mkt cap 33.66B*
P/E 16.91
Div/yield 2.69*
EPS 3.34*
Shares 600.50M
Beta     -
Inst. own     -
Oct 23, 2015
Q3 2015 Shire PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Jul 23, 2015
Q2 2015 Shire PLC Earnings Call
Jul 23, 2015
Q2 2015 Shire PLC Earnings Release
Jun 15, 2015
Shire PLC at Citi European Healthcare Conference
Jun 2, 2015
Shire PLC at Jefferies Global Healthcare Conference
May 7, 2015
Shire PLC at Deutsche Bank Health Care Conference

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 10.53% 54.47%
Operating margin 8.51% 28.20%
EBITD margin - 41.79%
Return on average assets 3.79% 29.88%
Return on average equity 7.27% 46.80%
Employees 5,016 -
CDP Score - 91 B


5 Riverwalk Citywest Business Campus, Dublin 24
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Phil J. Vickers Head of Research and Development
Age: 55
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 67
Olivier Bohuon Non-Executive Director
Age: 56
Dominic Blakemore Non-Executive Independent Director
Age: 45
William Burns Non-Executive Independent Director
Age: 67